GLOSTRUP, DENMARK--(Marketwire - May 11, 2011) - "As a leader in tissue-based cancer diagnostics, Dako is a company that to a large extent bases its development and success on proprietary innovations. We take great care to protect these innovations by patenting our technology in order to prevent competition from copying our innovative solutions and to ensure that Dako stays in the forefront of the market for tissue-based cancer diagnostics," says Dako CEO Lars Holmkvist.
Consequently, on May 3, 2011 Dako filed a complaint in the District Court of Delaware against Leica Microsystems for using Dako technology in their BondMax and Bond III immunohistostainers. The technology used by Leica is covered by two patents owned by Dako.
The two US patents, US 7,217,392 and US 7,553,672, held by Dako, cover the individual slide heating technology which among other products is used in Artisan, Dako's market leading special staining product. The patents have previously been licensed to Ventana Medical Systems.
About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and being present in more than 80 countries, Dako covers essentially all of the anatomic pathology markets globally. Dako is owned by a private equity fund, EQT. www.dako.com
